144 related articles for article (PubMed ID: 32768947)
1. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T
Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947
[TBL] [Abstract][Full Text] [Related]
2. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
3. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
Rodríguez-Fonseca RA; Sixto-López Y; Fragoso-Vázquez MJ; Flores-Mejía R; Cabrera-Pérez LC; Vázquez-Moctezuma I; Rosales-Hernández MC; Bello M; Martínez-Archundia M; Trujillo-Ferrara JG; Becerra-Martínez E; Correa-Basurto J
Anticancer Agents Med Chem; 2017; 17(10):1441-1454. PubMed ID: 28044941
[TBL] [Abstract][Full Text] [Related]
5. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
6. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
9. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
10. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
11. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a fluorescent probe with HDAC6 selective inhibition.
Zhang Y; Yan J; Yao TP
Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
15. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study.
Abdulwahab HG; Mansour RE; Farghaly TA; El-Sehrawi HM
Bioorg Chem; 2024 May; 146():107284. PubMed ID: 38493640
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays.
Uba AI; Hryb M; Singh M; Bui-Linh C; Tran A; Atienza J; Misbah S; Mou X; Wu C
Life Sci; 2024 Feb; 338():122395. PubMed ID: 38181853
[TBL] [Abstract][Full Text] [Related]
19. Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
Tretbar M; Schliehe-Diecks J; von Bredow L; Tan K; Roatsch M; Tu JW; Kemkes M; Sönnichsen M; Schöler A; Borkhardt A; Bhatia S; Hansen FK
Eur J Med Chem; 2024 Jun; 272():116447. PubMed ID: 38714044
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]